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Whole gene deletions or duplications are an important cause of genetic disease and phenotypic variation. Targeted
techniques for the routine testing of gross rearrangements have become essential tools for diagnostic researchers with the
search for the most cost-effective and efficient tool assuming high priority. We used the new selector technique, MLGA
(multiplex ligation-dependent genome amplification), to confirm deletions in two genes, SOX2 (SRY [sex determining
region Y]) box 2) and OTX2 (orthodenticle homeobox 2), in individuals with developmental eye disease. We conclude
that MLGA has the potential to be a useful technique in diagnostic research for the identification of deletions or duplications
of known genes due to its speed and relatively low cost.
Copy number variation (CNV) including submicroscopic
deletions, insertions, and duplications of DNA sequences is
becoming  increasingly  recognized  as  both  an  important
source of genome variation and a common cause of genetic
disease [1-4]. Over recent years, a variety of techniques have
been designed to identify CNVs. Global microarray-based
approaches  such  as  array-CGH  (comparative  genomic
hybridization) are widely used to detect CNVs on a genome
wide scale, but costs are still relatively high compared to
targeted approaches. Simple targeted approaches such qPCR
(quantitative  polymerase  chain  reaction)  and  FISH
(fluorescence in situ hybridization) are well established but
restrictive due to their inability to be multiplexed and their
labor-intensive  nature.  Techniques  without  these
shortcomings  such  as  multiplexed  targeted  approaches
including MAPH (multiplex amplifiable probe hybridization)
[5],  QMPSF  (quantitative  multiplex  polymerase  chain
reaction of short fluorescent fragments) [6], PRT (paralogue
ratio test) [7], and MLPA (multiplex ligation-dependent probe
amplification), which is perhaps the most commonly used
[8], have become essential tools for the routine detection of
both  large  deletions/duplications  and  exonic/single  gene
CNVs.  Indeed,  we  have  recently  used  MLPA  to  detect
deletions in SOX2 (SRY (sex determining region Y)-box 2),
OTX2  (orthodenticle  homeobox  2)  and  BMP4  (bone
morphogenetic  protein  4),  genes  involved  in  severe  eye
abnormalities [9-11]. However, despite its simple and robust
nature, MLPA is still relatively expensive and suggests the
need for a more cost-effective method of detecting CNVs.
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We  evaluated  a  new  selector  technique,  multiplex
ligation-dependent  genome  amplification  (MLGA),  which
has the potential to significantly reduce cost and turnaround
time. In MLGA, size-coded genomic DNA fragments are
circularized  and  undergo  multiplex  amplification  using
universal primers [12]. The time taken per MLGA assay is
less than 5 h with only three brief steps required before PCR
amplification.  Only  one  probe  is  required  per  target  (as
opposed to two in MLPA), and the running costs are less than
a  fifth  of  the  cost  of  MLPA.  However,  no  follow-up
publications to the initial report have emerged, and despite its
potential, MLGA has yet to be validated in a human diagnostic
setting. We evaluated the use of MLGA to detect known
deletions  in  five  patients  with  severe  developmental  eye
anomalies.
METHODS
Patients  with  developmental  eye  anomalies  (anophthalmia
and/or microphthalmia) were recruited to this study as part of
a national study based at Moorfields Eye Hospital (London,
UK)  and  Birmingham  Children’s  Hospital  (Birmingham,
UK). Written informed consent was obtained from all patients
in accordance with the ethics approval, which was obtained
for  the  study  from  Cambridgeshire  Research  Ethics
Committee  1  04/Q0104/129  (Cambridge,  UK).  Genomic
DNA  was  extracted  from  whole  blood  using  standard
protocols.
MLGA  was  performed  according  to  the  protocol
described by Isaksson et al. [12], using their oligonucleotide
sequences for the vector and universal primers. In essence,
genomic DNA was digested by the restriction enzyme, MnlI.
Restricted  fragments  were  then  circularized  in  a  ligation
reaction  with  the  selector  probes  (see  below)  and  vector
oligonucleotide. The vector hybridizes to the central part of
the selector probe, creating a HindIII recognition site and
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1445universal primer binding sites. Following the exonuclease I
treatment to eliminate non-circularized DNA, PCR with the
universal  primer  pair  amplified  the  selected  targets.  The
restriction enzyme, HindIII, was used during the PCR reaction
to create a linear template for amplification. PCR products
were  run  on  an  ABI  Prism®  3130  (Applied  Biosystems,
Foster  City,  CA)  and  analyzed  using  ABI  GeneMapper®
(Applied Biosystems). All probes were initially tested in a
cohort of 48 DNA samples without any gross rearrangements
at  the  interrogated  loci  with  probes  for  the  X  and  Y
chromosome  (AR  [androgen  receptor]  and  SRY  [sex
determining region Y], respectively) to allow for experimental
validation in the form of sex confirmation. The five positive
cases with known deletions (Table 1) were tested with five
normal  control  samples.  Each  assay  was  conducted  in
duplicate. Normalization of each sample trace was performed
by dividing each peak area by the sum of its nearest two
autosomal peak areas. Copy number ratio between samples
was determined by dividing each normalized peak area by its
mean across normal controls (as described [12]).
Selector probe design was performed as described by
Isaksson et al. [12] with two minor modifications, which is
described in the following. First, reference sequences were
obtained  from  the  UCSC  genome  browser  [13]:  OTX2
(GenBank  accession  number  NM_172337.1),  SOX2OT
(SOX2  overlapping  transcript)  (GenBank  RNA  accession
number BC041898.2), and autosomal control gene, NPM1
(nucleolar  phosphoprotein  B23,  numatrin)  (GenBank
accession number NM_002520.5). Second, newly designed
selector probe and fragment sequences were uploaded to the
BLAT  alignment  tool  [14]  to  check  for  single  nucleotide
polymorphisms (SNPs) within probe hybridization sequences
and length polymorphisms in the fragments. The overlapping
transcript of SOX2 (SOX2OT) was selected for interrogation
due to the relative ease of optimization compared with the GC-
rich SOX2 itself. In addition to the control probe, NPM1,
mentioned above, selector probes for control genes, MADH4
(mothers against decapentaplegic homolog 4), SRY, and AR,
were used as designed by Isaksson et al. [12]. Oligonucleotide
sequences are shown in Table 2.
RESULTS
The ABI GeneMapper® traces demonstrated a proportional
reduction in the peak area of the OTX2 fragment in all three
individuals  (cases  1–3)  with  previously  identified  OTX2
deletions and a proportional reduction in the peak area of the
SOX2 locus fragment in individuals (cases 4 and 5) with
previously  identified  deletions  of  the  entire  SOX2  locus
(Figure 1 for traces and graphs of OTX2 and SOX2 locus
deletions). Each result was confirmed in a second assay.
DISCUSSION
Our results demonstrate that MLGA can identify whole gene
deletions  in  a  human  diagnostic  research  setting  as
TABLE 1. DETAILS OF THE KNOWN DELETIONS IN CASES 1–5.
Case Previously detected by
Extent of deletion
Method Region
1 MLPA [11] Oligo array-CGH chr14:56,268,037–57,541,514
2 MLPA [9] Deletion cytogenetically visible 46XX del(14)(q22.3q23.2)
3 MLPA [11] Oligo array-CGH chr14:53,758,044–56,834,649
4 MLPA [10] Unknown
5 MLPA [10] Unknown
Table showing method(s) of detection and extent of the gene deletions where known in cases 1-5.
TABLE 2. LIST OF OLIGONUCLEOTIDES USED IN THE MLGA PROTOCOL.
Oligonucleotide Sequence (5′→3′)
SOT2OT CTCTTAGCTTGGTTTCCTCCAGTCCACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGTTTTGA
AAACAGACGATAGAAGTCT
OTX2 CCAATTCACTCCCCCCTCTAGCACACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGCAGAAT
GGAGGTCAAAACAAAGTGA
NPM1 GTCCCGCCTCCGCGCGACGATAACGGTAGAAAGCTTTGCTAACGGTCGAGCTCATGTCCATGTC
CATCGAATCTT
Vector CTCGACCGTTAGCAAAGCTTTCTACCGTTATCGT
Forward primer AGCTTTGCTAACGGTCGAG
Reverse primer AGCTTTCTACCGTTATCGT
Table showing oligonucleotide sequences for additional selector probes (SOX2OT, OTX2  and  NPM1 ) not described in the
original MLGA report by Isakson et al. [12], the vector used during circularisation and the universal primers used for multiplex
amplification.
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1446exemplified  by  the  diagnosis  of  human  OTX2  and  SOX2
deletions  in  developmental  eye  anomalies.  For  MLGA  to
become widely used in a diagnostic service setting, further
detailed validation work is required to prove reproducibility
in a large number of positive cases and controls. However, the
low running costs along with the ease and speed of the assay
would be particularly attractive to human genetic diagnostic
laboratories requiring regular CNV screens of known disease
loci.  By  amplifying  genomic  DNA  rather  than  probe
molecules, MLGA assays offer the potential to screen at least
50 loci in one assay by using several vectors and multiple
labels on the universal primers. Although the routinely used
technique, MLPA, is able to analyze this number of loci,
MLGA  has  the  potential  to  do  this  faster  and  more
economically. Furthermore, MLGA provides great flexibility
in the choice of target loci through the library of restriction
enzymes  available  to  create  fragments  for  subsequent
circularization and amplification.
MLGA  still  requires  further  validation  when
multiplexing up to 40-50 loci for it to be deemed as useful as
other multiplex targeted approaches (including MLPA) in
CNV detection. Moreover, significantly multiplexed assays
may require more stringent selector probe design criteria and
a more thorough initial optimization of reaction conditions
than MLPA since genomic DNA rather than designed probe
sequences are amplified. Aside from repetitive elements, most
of the genome is accessible to MLGA with only high GC
content (>60%) known to affect probe success rates [12].
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One significant advantage that MLGA does possess but
was not noted in the initial report is the capacity to provide
data on insertion-deletion polymorphisms or mutations with
a target sequence of interest. For example, a two base pair
deletion within a target sequence will give a shifted peak on
the GeneMapper® trace and thus may indicate an avenue for
further investigation, such as sequencing. This potential may
prove valuable to a researcher screening for mutations as well
as  deletions,  providing  a  useful  ‘pre-screen’  to  detect
intragenic deletions or insertions.
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